Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Enasidenib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2023 Planned number of patients changed from 105 to 63.
- 13 Mar 2023 Planned End Date changed from 28 Feb 2023 to 28 Feb 2025.
- 13 Mar 2023 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2025.